March 24, 2021 02:27 PM EDT

Teva sees room for growth with FDA communications and complex generics, COO says

Zachary Brennan

Senior Editor

While embroiled in legal battles, generic drug giant Teva Pharmaceuticals is hoping to turn a corner with the FDA in improving their communications and focus …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teva sees room for growth with FDA communications and complex generics, COO says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Te­va sees room for growth with FDA com­mu­ni­ca­tions and com­plex gener­ics, COO says

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Teva sees room for growth with FDA communications and complex generics, COO says